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Abstract
Background The aim was to compare the prognostic accuracy of cross-sectional imaging of the 7th and 8th editions of the
American Joint Committee on Cancer(AJCC) staging system for perihilar cholangiocarcinoma(PHC).
Methods All patients with PHC between 2002 and 2014 were included. Imaging at the time of presentation was reassessed and
clinical tumor–node–metastasis (cTNM) stage was determined according to the 7th and 8th editions of the AJCC staging system.
Comparison of the prognostic accuracy was performed using the concordance index (c-index).
Results A total of 248 PHC patients were included;45 patients(18.1%) underwent a curative-intent resection, whereas 203
patients(81.9%) did not because they were unfit for surgery or were diagnosed with locally advanced or metastatic disease during
workup. Prognostic accuracy was comparable between the 7th and 8th editions (c-index 0.57 vs 0.58). For patients who
underwent a curative-intent resection, the prognostic accuracy of the 8th edition (0.67) was higher than the 7th (0.65). For
patients who did not undergo a curative-intent resection, the prognostic accuracy was poor in both the 7th as the 8th editions (0.54
vs 0.57).
Conclusion The 7th and 8th editions of the AJCC staging system for PHC have comparable prognostic accuracy. Prognostic
accuracy was particularly poor in unresectable patients.
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Introduction
Perihilar cholangiocarcinoma (PHC) is the most common ma-
lignancy of the bile ducts.1 Overall survival differs strongly
between PHC patients, ranging from 12 months in palliative
treatment to 40 months after curative-intent resection.2–4
Prognostic studies typically focus on patients undergoing
curative-intent resection. However, the majority of patients
with PHC have metastatic or locally advanced disease at the
time of presentation.2,5–7
One of the most commonly used staging systems is the
American Joint Committee on Cancer (AJCC) staging system.
Recently, the AJCC released the AJCC 8th edition cancer
staging manual, which came into effect on January 1, 2018.
The 7th edition of the AJCC staging system was the first to
stage PHC and distal cholangiocarcinoma separately. The new
8th edition for PHC contains four significant changes
(Tables 1 and 2). Bilateral second-order bile duct involvement
(i.e., Bismuth classification IV) is no longer classified as T4 in
the 8th edition. Other reasons for T4 (e.g., main portal vein
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involvement) are reclassified as stage IIIb rather than stage
IVa. Positive lymph nodes beyond the hepatoduodenal liga-
ment (e.g., aortocaval or celiac nodes) have become M1 dis-
ease (stage IVb) rather than N2 disease in the 7th edition.
Instead, in the 8th edition, N2 disease (stage IVa) is classified
as 4 or more positive regional lymph nodes.
AJCC staging systems are intended to be applicable to all
cancer patients, regardless whether they undergo curative-
intent resection, palliative treatment, or best supportive care.
As the majority of patients with PHC is not eligible for
curative-intent resection, the AJCC staging involves assess-
ment of cross-sectional imaging in most patients, rather than
pathological evaluation of resected tumor specimens.
Therefore, the aim of this retrospective study was to evaluate
the 8th edition of the AJCC staging system for all patients with
PHC and compare the prognostic value of the 7th and 8th
editions of the AJCC staging system for PHC.
Materials and Methods
Study Population and Data Acquisition
All patients with PHC between 2002 and 2014 in Erasmus
MC University Medical Center, Rotterdam, the Netherlands,
were included. PHC was defined as a mass or malignant-
appearing stricture at or near the biliary confluence, arising
between the origin of the cystic duct and the segmental bile
ducts.8 A multidisciplinary team diagnosed PHC based on
clinical characteristics, radiological characteristics, endoscop-
ic findings, and follow-up, if histopathological evidence was
not available.9 Patient and tumor characteristics, clinical pa-
rameters, and laboratory results were retrospectively collected
from electronic patient records.
Experienced abdominal radiologists revised all imaging
from the time of first presentation. Tumor diameter, presence
and location of suspicious lymph nodes, presence of distant
metastases, and vascular involvement was reassessed.
Suspicious lymph nodes were defined as nodes larger than
1.0 cm in short-axis diameter, with central necrosis, an irreg-
ular border, or hyper-attenuation compared to liver parenchy-
ma in the portal-venous contrast-enhancement phase.9,10
Vascular involvement was defined as tumor contact of at least
180 degrees to the unilateral or main portal vein or hepatic
artery.9 Tumor–node–metastasis (TNM) stage was determined
Table 1 American Joint Committee on Cancer (AJCC) staging system by tumor–node–metastasis (TNM) stage on imaging
Stage AJCC, 7th edition AJCC, 8th edition
Tumor (T) stage
T1 Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue
T2a Tumor invades beyond the wall of the bile duct to surrounding adipose tissue
T2b Tumor invades adjacent hepatic parenchyma
T3 Tumor invades unilateral branches of the PVor HA
T4 Tumor invades main PVor its branches bilaterally, or the common
hepatic artery, second-order bile ducts bilaterally, unilateral
second-order bile ducts with contralateral portal vein or hepatic
artery involvement
Tumor invades main PVor its branches bilaterally, or the common hepatic
artery, or unilateral second-order biliary radicals with contralateral portal
vein or hepatic artery involvement.
Node (N) stage
N0 No regional lymph node metastasis No regional lymph node metastasis
N1 Regional lymph node metastasis: hilar (along CBD, cystic duct,
HA, or PV)
One to three positive lymph nodes typically involving the hilar, cystic duct,
common bile duct, hepatic artery, posterior pancreatoduodenal, and
portal vein lymph nodes
N2 Metastasis to periaortic, pericaval, SMA, or coeliac lymph nodes Four or more positive lymph nodes from the sites described for N1
Metastasis (M) stage
M0 No distant metastasis No distant metastasis
M1 Distant metastasis Distant metastasis (includes lymph node metastasis distant to the
hepatoduodenal ligament)
Table 2 American Joint Committee on Cancer (AJCC) staging system
AJCC, 7th edition AJCC, 8th edition
Stage T N M Stage T N M
0 is 0 0 0 is 0 0
I 1 0 0 I 1 0 0
II 2 0 0 II 2a-b 0 0
IIIa 3 0 0 IIIa 3 0 0
IIIb 1–3 1 0 IIIb 4 0 0
– 0 IIIc Any 1 0
IVa 4 Any 0 IVa Any 2 0
IVb Any
Any
2
Any
0
1
IVb Any Any 1
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according to both the 7th and 8th editions of the AJCC staging
system (Table 1). TNM stages I and II were combined, since
cT1 (stage I) and cT2 (stage 2) cannot be reliably distin-
guished on imaging.11 The Institutional Review Boards of
Erasmus MC University Medical Center approved the study,
and the need for informed consent was waived.
Statistical Analyses
Statistical analyses were performed using IBM SPSS
Statistics for Windows version 21.0 (IBM Corp.,
Armonk, NY, USA) and R (a language and environment
for statistical computing) version 3.3.3 for Windows (R
Foundation for Statistical Computing, Vienna, Austria).
Continuous data are reported as mean with standard devi-
ation (SD) or median with interquartile range (IQR).
Categorical parameters are reported as counts and percent-
ages. Survival was measured from the date of first presen-
tation. Survival probabilities were estimated using the
Kaplan–Meier method and compared with the log-rank
test. Survival status was updated using the municipal re-
cords database on December 21, 2017.
Comparison of the staging systems was performed using
the concordance index (c-index) and Brier score. The concor-
dance index is used to evaluate whether a staging system can
correctly discriminate between two patients at different stages
of disease. It is calculated as the probability that for two ran-
dom patients with different stages, the patient at the lower
stage has a longer survival. A c-index of 0.5 means that the
predictive ability is no better than random chance. A c-index
of 0.7 indicates a good model and an c-index of 1 means
perfect prediction. The Brier score is used to measure the
difference between observed and predicted survival per stage.
As opposed to c-indices, a lower Brier score is better and a
score of 0 means total accuracy, while a score of 0.250 indi-
cates no prognostic value.
Results
Patient Characteristics
A total of 248 patients were included; 45 patients (18.1%)
underwent a curative-intent resection and 203 patients
(81.9%) did not undergo a curative intent resection because
they were unfit for surgery or were diagnosed with locally
advanced or metastatic disease during workup (Fig. 1).
Patient characteristics are summarized in Table 3. Patient char-
acteristics are summarized in Table 3. The median age was
65 years (IQR 55–73) and 150 patients (60.5%) were male.
Most patients (n = 106, 44.0%) had an ECOG performance
status of 0 and 87 patients (35.1%) had a tumor larger than
3 cm on imaging. Unilateral involvement of the portal vein
Fig. 1 Flow diagram of patient cohort
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was observed in 87 patients (35.2%) and main/bilateral in-
volvement in 38 (15.4%). Unilateral involvement of the he-
patic artery was observed in 107 patients (43.1%) and
main/bilateral involvement in 27 (10.9%). The median OS
(95% confidence interval (CI)) of the entire cohort was
9.7 months (8.0–11.5).
Staging and Stage Transitions
The 7th edition of the AJCC staging categorized 33 (13.3%)
patients in TNM stage I/II, 78 (31.5%) in stage IIIA, 25
(10.1%) in stage IIIB, 41 (16.5%) in stage IVA, and 71
(28.6%) patients in stage IVB. The 8th edition of the AJCC
staging categorized 33 (13.3%) patients in stage I/II, 78
(31.5%) in stage IIIA, 11 (4.4%) in stage IIIB, 35 (14.1%) in
stage IIIC, 20 (8.1%) in stage IVA, and 71 (28.6%) patients in
stage IVB.
Tables 4 and 5 is a cross-tabulation of stage distribution and
transitions for the AJCC stages for the 7th and 8th editions. A
total of 53 patients (21.4%) were reclassified when consider-
ing substages (e.g., stage IIIa and IIIb) and 35 patients (14.1%)
considering only the major stages (i.e., stage I, II, III, or IV).
Staging according to the 8th edition upstaged 25 patients
(10.1%) and downstaged 28 patients (11.3%) of patients in
comparison with the 7th edition. Patients with N1 disease
(stage IIIb) in the 7th edition were upstaged to IIIc (if 1–3
positive lymph nodes) or IVa (if 4 or more positive lymph
nodes) in the 8th edition. Most patients with T4 disease (stage
IVa) in the 7th edition were downstaged to IIIb (if node-
negative) or IIIc (if 1–3 positive lymph nodes) in the 8th
edition.
Survival across Stages
The median OS for patients staged according to the 7th or 8th
edition per TNM stage were as follows: stage I/II (17.0 vs.
17.0 months), stage III (10.5 vs. 10.9 months), and stage IV
(7.03 vs. 5.6 months), respectively (p value between stages in
Table 3 Baseline characteristics
(n = 248) Characteristic All patients
(n = 248)
Curative-intent
resection (n = 45)
No resection
(n = 203)
Age at first presentation (years) 65 (55–73) 63 (52–71) 65 (56–73)
Gender, male 150 (60.5) 28 (62.2) 122 (60.1)
Primary sclerosing cholangitis 19 (7.6) 4 (8.9) 15 (7.4)
BMI (kg/m2) 24.8 (22.4–27.3) 25.0 (22.1–26.7) 24.8 (24.8–27.5)
ECOG performance status
0 107 (44.0) 21 (47.7) 85 (43.1)
1 86 (35.4) 14 (31.8) 72 (36.5)
2 37 (15.2) 7 (15.9) 29 (14.7)
3 13 (5.3) 2 (4.5) 11 (5.6)
Jaundice at presentationa 192 (80.3) 34 (79.1) 158 (80.6)
CA 19.9 (U/mL)2 ≥ 1000 U/mLb 46 (27.5) 2 (4.4) 44 (21.7)
Tumor size > 3 cm on imaging 87 (35.2) 7 (15.6) 80 (39.6)
Blumgart stage
1 71 (29.2) 16 (36.4) 55 (27.6)
2 61 (25.1) 12 (27.3) 49 (24.6)
3 111 (45.7) 16 (36.4) 95 (47.7)
Portal vein involvementc
Unilateral involvement 87 (35.2) 12 (26.7) 75 (37.1)
Main/bilateral involvement 38 (15.4) 2 (4.4) 36 (17.8)
Hepatic artery involvementc
Unilateral involvement 107 (43.1) 15 (33.3) 92 (45.3)
Main/bilateral involvement 27 (10.9 2 (4.4) 25 (12.3)
Categorical parameters are presented as counts (percentages) and continuous parameters as median (interquartile
range)
BMI body mass index, ECOG Eastern Cooperative Oncology Group, CA 19.9 carbohydrate antigen 19.9;
aMissing data for 9 patients
bMissing data for 81 patients
c Tumor contact of at least 180 degrees to the portal vein or hepatic artery and includedmain, bilateral, or unilateral
involvement on contrast-enhanced CT or MRI imaging
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the 7th edition = 0.085 vs. p value between stages in the 8th
edition = 0.015). Figures 2 and 3 show the Kaplan–Meier
curves for OS for the main stages of the 7th and 8th editions.
Prognostic Accuracy
Table 6 shows the concordance indices and Brier scores for
the two editions of the AJCC staging system. Prognostic ac-
curacy of the 8th editions of the main stages of the AJCC
staging systems was slightly higher than the 7th edition (c-
index 0.59 vs 0.61). Expanding the 7th edition to include
substages (e.g., IIIa and IIIb) slightly diminished its prognos-
tic accuracy (c-statistic from 0.59 to 0.57). Expansions of the
8th edition also diminished its prognostic accuracy (c-statistic
from 0.61 to 0.58). Prognostic accuracy was comparable be-
tween the expanded 7th and 8th AJCC staging systems (c-
index 0.57 vs 0.58).
Subgroup analysis was performed to determine the prog-
nostic accuracy of the AJCC staging system editions across
treatment groups (Table 6). In both the 7th as the 8th editions,
the AJCC staging system performed better in the subgroup of
patients who underwent a curative-intent resection compared
to the entire cohort (0.65 vs 0.57 in the 7th edition, 0.67 vs
0.58 in the 8th edition). The 8th edition did have a slightly
better prognostic value compared to the 7th edition in this
subgroup (c-index of 0.65 vs 0.67).
Although the prognostic accuracy of the 8th edition of the
AJCC staging system in patients who did not undergo a resec-
tion was slightly better when compared to the 7th edition
(0.54), the prognostic accuracy was still very poor with a c-
index of 0.57 in both the main as expanded staging system.
Discussion
In our all-comer cohort, we found that the prognostic accuracy
of cross-sectional imaging for patients presenting with PHC
was comparable across the 7th and 8th AJCC staging systems
(c-index 0.57 vs 0.58). The prognostic accuracy of the 8th
edition was higher in patients who underwent a curative-
Table 5 Cross-tabulation of the substages of the 7th and 8th editions of
the American Joint Committee on Cancer (AJCC) staging system
8th edition
I/II IIIa IIIb IIIc IVa IVb Total
7th edition I/II 33 0 0 0 0 0 33
IIIa 0 78 0 0 0 0 78
IIIb 0 0 0 18 7 0 25
IVa 0 0 11 17 13 0 41
IVb 0 0 0 0 0 71 71
Total 33 78 11 35 20 71 248
Each row shows how many patients at a specific 7th edition stage
transitioned to other stages according to the 8th edition. Numbers in
red refer to patients who moved to a different stage from the 7th
to the 8th edition
Table 4 Cross-tabulation of the main stages of the 7th and 8th editions
of the American Joint Committee on Cancer (AJCC) staging system
8th edition
I/II III IV Total
7th edition I/II 33 0 0 33
III 0 96 7 103
IV 0 28 84 112
Total 33 124 91 248
Each row shows how many patients at a specific 7th edition stage
transitioned to other stages according to the 8th edition. Numbers in
red refer to patients who moved to a different stage from the 7th
to the 8th edition
Fig. 2 Kaplan–Meier curves for OS for the main stages of the 7th edition
Fig. 3 Kaplan–Meier curves for OS for the main stages of the 8th edition
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intent resection compared with those who did not (0.67 and
0.57). Although prognostic accuracy of the 8th edition in pa-
tients who did not undergo a curative-intent resection was
slightly better than the 7th edition, the prognostic accuracy
of the AJCC staging system in these patients was still poor
with a c-index of 0.57.
The 8th edition AJCC staging system included four major
modifications (Table 1). These modifications resulted in re-
classification of 53 (21.4%) patients with consideration of
substages (e.g., stages IIIa and IIIb) and 35 (14.1%) patients
considering only the major stages. However, these modifica-
tions and concomitant reclassifications failed to significantly
improve its prognostic accuracy.
Other studies evaluated the prognostic accuracy of the 7th
edition of the AJCC staging system.12–14 However, TNM
stages were based on pathological evaluation (pTNM) of the
resected specimen, rather than evaluating cross-sectional im-
aging (cTNM) as was performed in the present study. These
studies excluded most PHC patients, because only a minority
of PHC patients is eligible for a curative-intent resection. A
large study comparing the 6th and 7th editions of the AJCC
staging system in a cohort of 306 patients who underwent a
resection found similar prognostic accuracy for the 7th edition
with a c-index of 0.59 using only the main stages and 0.54
using substages.12 . A Japanese study evaluated the 7th edition
of the AJCC staging system and proposed a modified
system.13 This modification was the basis for the modification
in T stage implemented in the 8th edition of the AJCC staging
system: Bismuth type IV tumors were no longer considered as
T4 and T4 tumors were downstaged from stage IVA to IIIb.
However, external validation showed that the modified model
did not improve prognostic accuracy compared to the 6th and
7th editions of the AJCC staging system.12
This is the first study to evaluate the 8th edition of the
AJCC staging system for all patients with PHC, regardless
of subsequent treatment. AJCC stages were assigned based
on cross-sectional imaging (cTNM). Stage assignment based
on pathological evaluation (i.e., pTNM) was not possible, be-
cause most patients with PHC have locally advanced or met-
astatic disease or are unfit to undergo major surgery and there-
fore do not undergo a resection. Nevertheless, this study has
some limitations that should be mentioned. The TNM stage
was determined on cross-sectional imaging in all patients with
PHC, rather than using pathological examination of resected
specimens. Vascular involvement and the biliary extent of the
tumor are often difficult to determine on cross-sectional im-
aging. However, the AJCC staging system is specifically de-
veloped to apply on both cross-sectional imaging and patho-
logical examination of all PHC patients. In future studies, we
would like to compare clinical and pathological staging,
which would require detailed pathological reporting.
Because most patients with PHC have locally advanced or
metastatic disease at presentation (or are unfit for major sur-
gery), the prognostic accuracy of AJCC staging system edi-
tions should be based on cross-sectional imaging rather than
pathological evaluation. In addition, staging has the most po-
tential clinical implications in the preoperative period, where it
can still influence the decision whether to try and perform a
resection or not. Accuracy on imaging is therefore arguably
the most important parameter. Future editions of the AJCC
staging system should aim to improve the prognostic accuracy
of AJCC staging system on cross-sectional imaging.
Conclusions
The prognostic accuracy of the 8th edition of the AJCC stag-
ing system was similar to the 7th edition. Prognostic accuracy
was particularly poor in the majority of PHC patients who did
not undergo a resection. Future editions of the AJCC staging
system should aim to improve the prognostic accuracy of
AJCC staging system on cross-sectional imaging.
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